Read Summary

With up to a quarter of nonsmall-cell lung cancer patients treated with pembrolizumab “around 5 years from now, that completely changes our mindset,” says David Graham, MD, Levine Cancer Institute.
Medscape Medical News

Print Friendly, PDF & Email